title: Antibacterial activities of amorphous cefuroxime axetil ultrafine particles prepared by high gravity antisolvent precipitation (HGAP).
abstract: In vitro and in vivo antibacterial activities on the Staphylococcus aureus and Escherichia coli of the amorphous cefuroxime axetil (CFA) ultrafine particles prepared by HGAP method were investigated in this paper. The conventional sprayed CFA particles were studied as the control group. XRD, SEM, BET tests were performed to investigate the morphology changes of the samples before and after sterile. The in vitro dissolution test, minimal inhibitory concentrations (MIC) and the in vivo experiment on mice were explored. The results demonstrated that: (i) The structure, morphology and amorphous form of the particles could be affected during steam sterile process; (ii) CFA particles with different morphologies showed varied antibacterial activities; and (iii) the in vitro and in vivo antibacterial activities of the ultrafine particles prepared by HGAP is markedly stronger than that of the conventional sprayed amorphous particles.
authors.affiliation: Sin-China Nano Technology Center, Key Lab for Nanomaterials, Ministry of Education, Beijing University of Chemical Technology, Beijing 10029, PR China.
authors.forename: Hong
authors.initials: H
authors.lastname: Zhao
authors.forename: Xu-liang
authors.initials: XL
authors.lastname: Kang
authors.forename: Xuan-li
authors.initials: XL
authors.lastname: Chen
authors.forename: Jie-xin
authors.initials: JX
authors.lastname: Wang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Le
authors.forename: Zhi-gang
authors.initials: ZG
authors.lastname: Shen
authors.forename: Jian-feng
authors.initials: JF
authors.lastname: Chen
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000032:analysis* / Q000494:pharmacology / Q000627:therapeutic use*; D002444:Cefuroxime / Q000031:analogs & derivatives* / Q000032:analysis / Q000494:pharmacology / Q000627:therapeutic use; D011232:Chemical Precipitation; D004339:Drug Compounding; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy*; D051379:Mice; D008813:Mice, Inbred ICR; D010316:Particle Size; D012995:Solubility; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects; D014961:X-Ray Diffraction
chemical_list: D000900:Anti-Bacterial Agents; D002444:Cefuroxime; C040738:cefuroxime axetil